EGF Ointment for Erlotinib Skin Lesion
Epidermal growth factor receptor-tyrosin kinase inhibitor (EGFR-TKI, Erlotinib) has demonstrated its efficacy in patients with non-small cell lung cancer and pancreatic cancer. But, their use is associated with dermatologic reactions of varying severity. Incidence of Erlotinib related skin effect (ERSE) was reported ~75% in NSCLC and pancreatic cancer phase III trials. Even though the dermatologic reactions could be a surrogated marker, it may be cause of dose modification. Also, it could give significant physical and psycho-social discomfort to patients. However, there is still a wide variety of drugs used- including, steroid, antibiotics, and vitamin D without any clear evidence based management recommendation.
The role of epidermal growth factor (EGF) has been extensively investigated in normal and pathological wound healing. It is implicated in keratinocyte migration, fibroblast function and the formation of granulation tissue. The first growth factor to be isolated growth factor therapy has progressed into clinical practice in the treatment of wounds.
Therefore, the investigators propose an epidermal growth factor ointment apply for patients with Erlotinib related skin effects.
Non-small Cell Lung Cancer
Drug: Epidermal growth factor (EGF) ointment
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Trial of Epidermal Growth Factor Ointment for Patients With Erlotinib Related Skin Effects|
- Improvement of skin lesion grading by NCI-CTC v3.0 [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||May 2012|
|Study Completion Date:||October 2014|
|Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
|Experimental: EGF ointment||
Drug: Epidermal growth factor (EGF) ointment
EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as "no effect"
Other Name: Sesal Yeongo
Advances in the knowledge of tumor biology and mechanisms of oncogenesis has granted the singling out of several molecular targets for NSCLC treatment. Among these targets, epidermal growth factor receptor (EGFR), or HER1, has received particular attention in lung cancer treatment. EGFR is a transmembrane receptor found primarily on cells of epithelial origin. Autophosphorylation of its intracellular domain initiates a cascade of events leading to cell proliferation. EGFR is commonly expressed at a high level in a variety of solid tumors and it has been implicated in the control of cell survival, proliferation, metastasis and angiogenesis. The main pharmacological strategies in clinical development for therapeutic inhibition of EGFR are monoclonal antibodies to antagonize ligand-receptor binding, and small-molecules to inhibit tyrosine kinase domain activation. The main EGFR inhibitors are cetuximab, an anti-EGFR monoclonal antibody, and Erlotinib an EGFRtyrosine kinase inhibitor. The key indications for clinical use are colorectal cancer and head and neck cancer for cetuximab and NSCLC for Erlotinib. Erlotinib, a quinazolin-4-amine, is a highly potent, orally available, reversible inhibitor of EGFR tyrosine kinase. Erlotinib, in a phase III randomized placebo-controlled trial, has been proven to prolong survival (6.7 months versus 4.7 months for Erlotinib and for placebo respectively, p = 0.001) in NSCLC patients after first or second line chemotherapy. The analysis of quality of life and time to deterioration of patients reported symptoms showed statistically and clinically meaningful benefit for patients randomized to Erlotinib. Moreover, Erlotinib resulted active (response rate of 8.9%) and safe (only 5% of patients discontinued treatment for toxicity). Following this trial, Erlotinib has been approved by Food and Drug Administration and Committee for Medicinal Products for Human use in chemotherapy-pretreated advanced NSCLC. Skin rash is a common side-effect of all HER1/EGFR inhibitors.
Rash affecting the skin above the waist, is the most common adverse event associated with Erlotinib, and generally develops within 7-10 days of starting treatment. Skin rash may spontaneously resolve and reappear and it is reversible following drug discontinuation. However, when it develops, this chronic side-effect is very distressing for the patient. The increasing use of EGFR-targeted agents and specifically of Erlotinib in NSCLC treatment, and simultaneously the lack of clinical trials on this topic, makes rash management and etiology investigation high priorities.
It has been reported that repeated treatment with EGF increases the epithelial cell proliferation in a dose dependent manner and accelerates the wound healing process, whereas a single EGF treatment has no noticeable effect on the wound-healing rate. There have been many studies aimed at developing a topical formulation with the sustained and stable pharmacological properties of recombinant human EGF (rhEGF). And the rh-EGF concentration between 1 and 5 ug/g can be seen as the ideal concentration to achieve the most efficient results for acute wounds with partial thickness defects.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01593995
|Korea, Republic of|
|Dong-A University Hospital|
|Busan, Korea, Republic of, 602-715|
|Study Director:||Sung Yong Oh, M.D.,Ph.D.||Onclogy Division, Dong-A University Hospital|